Latest News and Events
Filter by
Selections
December 11, 2019
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreDecember 6, 2019
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
Read MoreDecember 4, 2019
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Read MoreDecember 2, 2019
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
Read MoreNovember 26, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
Read MoreNovember 18, 2019